Ceftazidime-avibactam: effectiveness and safety in the clinical practice. A third hospital level experience

CALVO-GARCÍA A1, IBAÑEZ ZURRIAGA MD1, RAMÍREZ HERRÁIZ E1, PÉREZ ABÁNADES M1, SÁEZ BEJAR C2, MORELL BALADRÓN A3

1 Pharmacist. Pharmacy Department
2 Doctor. Internal Medina Department
3 Head of Pharmacy Department
La Princesa University Hospital. Madrid (Spain)

SUMMARY

Objectives: Ceftazidime/avibactam (CZA) is a third generation cephalosporin and the first non-beta-lactam beta-lactamase inhibitor combination. The main outcome was to assess the effectiveness and safety of CZA in the clinical practice.

Methods: It was a retrospective observational study. The inclusion criteria were age >18 years and receipt of >24 hours of CZA between January 2016 and October 2018. Variables studied included demographic, clinical, and treatment.

Results: 63 inpatients in treatment with CZA were included, 39 (61.9 %) were male and the mean (SD) age was 64.3 (15.8) years. Thirty-eight (60.3%) patients presented bacteremia and 28 (44.4%) were admitted in Intensive Care Unit (ICU). Klebsiella pneumoniae were isolated in 43 (68.3) patients, and OXA-48 carbapenemase in 51 (81.0%). Concomitant antibiotic was used in 40 (63.5%) patients. Mortality at 14 and 30 days were 6 (9.5%) and 4 (6.3%) patients, respectively. Thirty-five (55.6%) patients reached microbiological cure and 47 (74.6%) clinical cure. Infection recurrence evaluated at 90 days was achieved in 23 (36.5%) patients. ICU admission and bacteremia showed decreased in clinical cure (p=0.023 and p=0.01, respectively). Only ICU admission had a diminution in microbiological cure (p=0.035) and bacteremia a higher recurrence evaluated at 90 days (p=0.003). Only 3 (4.8%) patients interrupted treatment because of the adverse events.

Conclusions: ICU admission had demonstrated a microbiological and clinical cure decreasing. Recurrence evaluated a 90 days was statically significant higher in patients with bacteremia. CZA was a security antibiotic, with a very low incidence of treatment interruptions.

Key words: Ceftazidime-avibactam, antibiotic resistance, enterobacteriaceae infections, nosocomial infections, carbapenemase-producing enterobacteriaceae, beta-lactamase, klebsiella pneumoniae.

Ceftazidima-avibactam: efectividad y seguridad en práctica clínica habitual. Experiencia de un hospital de tercer nivel

RESUMEN

Objetivo: Ceftazidime/avibactam (CZA) es una cefalosporina de tercera generación y el primer inhibidor de beta-lactamases no beta-lactámico. El objetivo principal fue evaluar su efectividad y seguridad en la práctica clínica.

Métodos: Se realizó un estudio observacional retrospectivo. Los criterios de inclusión fueron: edad >18 años y administración de >24 horas de CZA entre enero de 2016 y octubre de 2018. Las variables estudiadas incluyeron demográficas, clínicas y de tratamiento.

Resultados: Se incluyeron 63 pacientes con CZA, 39 (61,9 %) fueron hombres, media (3D) de edad de 64,3 (15,8) años. 38 (60,3%) pacientes presentaron bacteriemia y 28 (44,4%) fueron ingresados en la Unidad de Cuidados Intensivos (UCI). Klebsiella pneumoniae se aisló en 43 (68,3) pacientes y OXA-48 carbapenemase en 51 (81,0%). Concomitante antibiótico fue usado en 40 (63,5%) pacientes. La mortalidad a los 14 y 30 días fue de 6 (9,5%) y 4 (6,3%), respectivamente. Treinta y cinco (55,6%) alcanzaron curación microbiológica y 47 (74,6%) curación clínica. Recurrencia de la infección a los 90 días sucedió en 23 (36,5%). El ingreso en UCI y la bacteriemia demostraron una disminución de la curación clínica (p=0,023 y p=0,01, respectivamente). El ingreso en UCI tuvo una disminución en curación microbiológica (p=0,035) y la bacteriemia en una mayor recurrencia a los 90 días (p=0,003). 3 (4,8%) interrumpieron el tratamiento por toxicidad.

Conclusiones: El ingreso en UCI se relacionó con disminución de curación microbiológica y clínica. La recurrencia a los 90 días fue mayor en pacientes con bacteriemia. CZA presenta una incidencia baja de interrupciones del tratamiento.

Palabras clave: Ceftazidima-avibactam, resistencia antibiótica, enterobacteriaceae infecciones, nosocomial infecciones, enterobacteriaceae productoras-carbapenemasa, beta-lactamasa, klebsiella pneumoniae.
INTRODUCTION
The nosocomial infections by carbapenem-resistant Enterobacteriaceae (CRE) has increased in recent years. In some countries, this situation has become a public health problem due to these bacteria are now endemic. To address this problem, the World Health Organization (WHO) published Global Action Plan on Antimicrobial Resistance in 2015.

Most prevalent bacteria are included in Enterobacteriaceae family, such as Klebsiella pneumoniae, and Escherichia spp.; or Pseudomonadaeae family such as Pseudomonas spp. Klebsiella pneumoniae carbapenemase (KPC), Verona integrin-encoded metallo-β-lactamase (VIM) and β-lactamase OXA-48 are among the most frequent carbapenemases related with antibiotic resistance.

The main treatment for this kind of bacteria has been beta-lactam antibiotics and carbapenem antibiotics, nevertheless, beta-lactam resistance limits treatment options for this complicated infections.

Ceftazidime is a third generation cephalosporin against Enterobacteriaceae and Pseudomona spp. Avibactam, the first non-beta-lactam beta-lactamase inhibitor, has in vitro activity against class A (such as KPC), class B and class C carbapenemases (such as OXA-48). It has no activity against metallo-beta-lactamases (MBL), New Delhi metallo-β-lactamase (NDM) or VIM.

Ceftazidime/avibactam (CZA) combination was approved 24 June 2016 by European Medicines Agency (EMA) for treatment of complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI), including pyelonephritis, hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP) and infections due to aerobic Gram-negative organisms with limited treatment options.

There are not many clinical practice data due to recently CZA commercialization. In vitro activity against Enterobacteriaceae is between 67.0-99.0%. Therefore, it is important to determinate CZA susceptibility of the isolated bacteria and identify carbapenemase or beta-lactamase enzyme related to antibiotic resistance. A low rate of resistance development to CZA is reported, varying from 1.6-2.0%. Clinical response varies among 55.0-95.0% and microbiological response among 55.6-91.1%.

Complicated infection and comorbidities might reduce clinical and microbiological response to CZA. Therefore, concomitant antibiotic against isolated bacterium might be necessary. Nevertheless, increased response to concomitant treatment is not demonstrated versus CZA monotherapy. Infection recurrence after CZA treatment varies among 8.7-21.6%.

Therefore, nosocomial infections, resistance and the development of new antibiotics such CZA are increasing, we designed this study in clinical practice. The main outcome was to assess the effectiveness (defined as clinical and microbiological cure) and safety profile of CZA in clinical practice. The secondary objectives were to assess the effectiveness between subgroups of patients (patients with bacteremia, Intensive Care Unit (ICU) admission and concomitant antibiotic treatment), and to assess recurrence of infection.

MATERIALS AND METHODS
Study design
This was a retrospective observational study between January 2016 and October 2018. The inclusion criteria were: 1) age ≥18 years, and 2) receipt of >24 hours of CZA. After treatment had been finished, a monitoring period of ninety days was performed. Approval was obtained by the Clinical Research Ethics Committee of the University Hospital of La Princesa.

Variables and definitions
All patient data were collected from electronic history records and electronic prescribing system. Variables studied included demographic (age and sex), clinical (admission unit, Charlson Index of co-morbidities at admission and estimated glomerular filtration rate (eGFR) calculated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)), microbiological (infection source or focus, isolated bacteria, carbapenemase and/or beta-lactamase presence, bacteremia and ICU admission), and treatment (days until CZA treatment starting, CZA treatment duration, exceeded recommendations of time treatment by infection onset, treatment beginning causes, CZA dosage and loading dose (4g of ceftazidime and 2g of avibactam), CZA adjustment dose by eGFR (≥50 ml/min), previous systemic antibiotic use, concomitant systemic antibiotic use, CZA susceptibility (by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) antimicrobial susceptibility testing regulations), adverse events, causes of treatment discontinuation, clinical and microbiological cure, infection recurrence evaluated at 90 days, CZA treatment of the recurrence evaluated at 90 days and all-cause mortality during 14 and 30 days after starting CZA). Comorbidity burden was quantified using the Charlson comorbidity score. Clinical cure was defined as an absence of infection signs and fever registered in electronic history records. Microbiological cure was defined as a negative culture of focus infection after CZA treatment completion. The safety was registered as any adverse event related with treatment achieved in electronic medical record. Adverse event degree was classified according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. The infection were classified attending to Common Terminology Criteria for Adverse Events classification and CTCAE Version 5.0.

Statistics analysis
Baseline characteristics of the patients were evaluated using descriptive statistics (proportion of patients, means, standard deviation (SD), medians, interquartile range (IQR)). In the analysis of subgroup, Chi-squared test was performed to identify the association between effectiveness and infection recurrence evaluated at 90 days with ICU admission, bacteremia and concomitant antibiotic therapy. T-student test was applied to cooperate effectiveness and Charlson index. Results were considered statistically significant if the p-value was less than 0.05. All analyses were calculated using SPSS Version 22.0 software.
Ceftazidime-avibactam: effectiveness and safety in the clinical practice. A third hospital level experience

RESULTS

Between January 2016 and October 2018, 63 inpatients were treated with CZA; all of them were included in the study. The mean (SD) age was 64.3 (15.8) years and 39 (61.9%) patients were male. Sixteen (25.4%) patients were admitted in Hematology, 11 (17.35%) in Internal Medicine, and 7 (11.1%) in Digestive Surgery (distribution by admitted unit are shown in table 1A of Appendix). In 20 (31.7%) patients, CZA was administrated as expanded use, before CZA was commercialized. Charlson Index mean (SD) was 4.27 (3.0). Infection characteristics are presented in table 1.

Previously to starting treatment, CZA susceptibility was verified in 56 (88.9%) patients.

Mean (SD) time until start of CZA treatment was 9.7 (10.7) days, and mean treatment days was 13.2 (10.5). In 19 (30.1%) patients, recommendations of time treatment by infection onset were exceeded, with an average of 4.5 (16.6) days. Treatment characteristics are shown in table 2.

Effectiveness

Microbiological cure were reached in 35 (55.6%) and were not obtained in 14 (22.2%) patients. A bacterial culture of infection focus for microbiological cure confirmation were not performed in 14 (22.2%) patients. Forty-seven (74.6%) patients achieved infection clinical resolution and in 13 (20.6%) clinical cure were not evaluated. Clinical and microbiological cure proportion by infection source are shown in table 3.

Infection recurrence evaluated at 90 days was registered in 23 (36.5%) patients, average age 60.0 (16.0) years, and 12 (52.2%) received CZA retreatment. The most isolated bacteria was *K. pneumoniae*, in 15 (65.2%) patients, and OXA-48 was the most common enzyme 15 (78.3%). The mean duration of CZA treatment were 10 days and in 9 (75.0%) patients concomitant systemic antibiotic were used. None of the recurrences developed CZA resistance and all of them were resolved.

Safety

At least one side effect were registered in 7 (11.1%) patients and only one patient underwent two side effects. In 3 (4.8%) patients the treatment were interrupted because of the adverse events. In table 4 are resumed side effects frequency.

Subgroups analysis

Differences in effectiveness (clinical and microbiological cure) was analyzed by Pearson’s chi-squared test in difference subgroups shown in table 5.

Infection recurrence evaluated at 90 days, was higher in those with bacteremia (18 (60.0%) vs. 5 (20.0%) patients, p=0.003). No relation were found between ICU admission and infection recurrence during 90 days (12 (54.5%) vs. 11 (33.3%), p=0.118).

Median Charlson comorbidity Index was analyzed by Student’s t-test in patients who reached clinical cure (3.9 (2.9) vs. 5.38 (3.0), p=0.122) and microbiological cure (4.3 (3.1) vs. 4.8 (3.0), p=0.654).

DISCUSSION

The upward incidence of nosocomial infections by *Enterobacteriaceae* pathogens such as *Klebsiella pneumoniae*, *E. coli*, and *Pseudomonas* spp. is a health problem as WHO addressed in the Global Action Plan on Antimicrobial Resistance, published in 2015. Most of these pathogens has a broad spectrum of antimicrobial resistance based on carbapenemases and beta-lactamases enzymes. These factors complicate the treatment, increase treatment failure and mortality of nosocomial infections. The current strategy is to find new antibiotics and antibiotic-inhibitors combinations that are able to escape these resistance mechanisms. Therefore, we followed out this evaluation of effectiveness and safety of CZA, a novel antibiotic-inhibitor, in clinical practice.
In our cohort, the most frequent source of infection was intra-abdominal (31.7%) followed by urinary and pulmonary, similar to Sousa et al.\textsuperscript{8} and Shields et al.\textsuperscript{23,24}, and in contrast with other studies where pulmonary source was the most common\textsuperscript{21,22}. \textit{K pneumoniae} was the most CRE isolated (43%) followed by \textit{E coli} (11.1%) and \textit{P aeruginosa} (9.5%). These results contrast with the literature, but in our admission (44.4%) was lower than other cohorts\textsuperscript{21}. It could be due to in our study, there were a high proportion of patients admitted in hematology service (25.4%), where immunocompromised patients are more common.

<table>
<thead>
<tr>
<th>Causes of treatment discontinuation</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical/microbiological cure</td>
<td>45 (71.4)</td>
</tr>
<tr>
<td>Exitus</td>
<td>7 (11.1)</td>
</tr>
<tr>
<td>End of scheduled treatment</td>
<td>4 (6.3)</td>
</tr>
<tr>
<td>Treatment toxicity</td>
<td>3 (4.8)</td>
</tr>
<tr>
<td>Treatment failure</td>
<td>2 (3.2)</td>
</tr>
<tr>
<td>Other</td>
<td>2 (3.2)</td>
</tr>
</tbody>
</table>

In our study, a high proportion of clinical cure (74.6%) was reached, similar to reported in literature, ranging between 68.8-91.3\%\textsuperscript{6,7,8,9,10,26-28}. Almost half of the patients reached microbiological cure (55.6%), low proportion comparing with literature, where it varies between 65.0-91.2\%\textsuperscript{6,7,8,9,12,26,28,30}. Difference could be due to the fact that microbiological cure was not evaluated in 22.2\% of our patients. Infections due Gram-negative with limited treatment options reached the highest proportions of clinical and microbiological cure, followed by cUTI, in contrast with other studies where HAP reached more proportion of infection resolution\textsuperscript{22}. In a systematic review published by Zhong et al., clinical and microbiological response was superior in patients with cUTI, what could be explained by the renal excretion of avibactam\textsuperscript{28}.

Recurrence of infection evaluated at 90 days (36.5\%), was slightly higher than Sousa et al.\textsuperscript{8} and Alraddadi et al.\textsuperscript{22} studies (10.0\% and 20.0\% of recurrence at 90 days, respectively). None CZA resistance was achieved, even in infection recurrence, similar to low rates reported in literature, varying from 0-2.0\%\textsuperscript{6,9,10,28,29}.

Adverse event requiring discontinuation were only nec-
Effectiveness subgroup analysis showed ICU admission as poor prognostic factor for clinical and microbiological cure, with differences statistics significant. This could be due to the fact that the pharmacokinetics in critical patients of ceftazidime is well known, however more studies are required for avibactam

In the case of bacteremia, results are similar, but statistical significance were not reaching in microbiological cure, due to patients in whom microbiological cure were not registered.

When it comes to concomitant antibiotic treatment, no differences were found in effectiveness (clinical or microbiological cure), similar to found in Jorgensen et al. study.

In our cohort, bacteremia demonstrated the highest impact in recurrence infection evaluated at 90 days. Bacteremia can cause infection in a remote focus that may not be detected in blood cultures and promote the premature end of CZA treatment.

Our study has several limitations. First one, missing data due to retrospective design of the analysis could distort the results, for example, the loss of almost a quarter of microbiological resolution data. On the other hand, reasons of exceeding recommendations of time treatment were not analyzed. Finally, a small sample size could influence in statically power of the study.

In conclusion, CZA has demonstrated efficacy and safety in clinical trials, but data in regular clinical practice may be differ from them. The effectiveness, evaluated as clinical and microbiological cure, were similar to others real clinical practice studies, and could confirm CZA as election therapy in CRE infection with a good safety profile and a low discontinuation proportion due to adverse event. Some factors, as the ICU admission and bacteremia were related with less effectiveness and more 90 days infection recurrence. An early CRE identification was essential for reached infection resolution, especially in patients with those poor prognostic factors.

Conflict of interests: The authors declare that they do not present a conflict of interest.

### Table 3. Effectiveness by infection source

<table>
<thead>
<tr>
<th>Infection Source</th>
<th>Clinical cure n (%)</th>
<th>Microbiological cure n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections due Gram-negative with limited treatment options</td>
<td>16 (94.1)</td>
<td>11 (84.6)</td>
</tr>
<tr>
<td>Complicated intra-abdominal infection</td>
<td>13 (72.2)</td>
<td>9 (64.3)</td>
</tr>
<tr>
<td>Complicated urinary tract infection</td>
<td>10 (76.9)</td>
<td>9 (81.8)</td>
</tr>
<tr>
<td>Hospital-acquired pneumonia</td>
<td>8 (66.7)</td>
<td>6 (54.5)</td>
</tr>
</tbody>
</table>

### Table 4. Adverse events

<table>
<thead>
<tr>
<th>Side effect</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypernatremia Grade 1*</td>
<td>3 (4.8)</td>
</tr>
<tr>
<td>Hypernatremia Grade 2*</td>
<td>2 (66.7)</td>
</tr>
<tr>
<td>Lymphocyte count decreased (Grade 1*)</td>
<td>1 (1.6)</td>
</tr>
<tr>
<td>Neutrophil count decreased (Grade 4*)</td>
<td>1 (1.6)</td>
</tr>
<tr>
<td>Platelet count decreased (Grade 3*)</td>
<td>1 (1.6)</td>
</tr>
<tr>
<td>Myoclonus</td>
<td>1 (1.6)</td>
</tr>
<tr>
<td>Transaminases increase (Alanine aminotransferase and aspartate aminotransferase increased) (Grade 2*)</td>
<td>1 (1.6)</td>
</tr>
</tbody>
</table>

*: according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 of 2017 (18).

### Table 5. Effectiveness subgroup analysis

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Clinical cure (n=47)</th>
<th>Microbiological cure (n=35)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IU admission</td>
<td>31 (88.6%)</td>
<td>24 (68.6%)</td>
</tr>
<tr>
<td>Yes</td>
<td>16 (57.1%)</td>
<td>11 (39.3%)</td>
</tr>
<tr>
<td>Bacteremia</td>
<td>22 (88.0%)</td>
<td>15 (60.0%)</td>
</tr>
<tr>
<td>No</td>
<td>25 (65.8%)</td>
<td>20 (52.6%)</td>
</tr>
<tr>
<td>Yes</td>
<td>19 (82.6%)</td>
<td>13 (56.5%)</td>
</tr>
<tr>
<td>Concomitant systemic antibiotic therapy</td>
<td>28 (70.0%)</td>
<td>22 (55.0%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>p</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.023</td>
<td>0.035</td>
</tr>
<tr>
<td>0.010</td>
<td>0.058</td>
</tr>
<tr>
<td>0.251</td>
<td>0.569</td>
</tr>
</tbody>
</table>

### BIBLIOGRAPHY


